You are not logged in. | Log in
In Progress
Clinical

Effect of two weeks erythropoietin treatment on monocyte transcriptomes of cardiorenal patients-GSE17582

Purpose

The first aim was to investigate whether this short term treatment revealed non-hematopoietic EPO effects. The second aim was to address whether EPO dampens expression of genes involved in inflammation and oxidative stress. Given the variable response to EPO, the third aim was to test whether baseline gene expression profiles or the acute gene expression modulation by EPO are associated with EPO resistance.

Hypothesis

Monocyte gene expression profiles of cardiorenal patients compared to healthy controls reflect the systemic nature of CRS and are responsive to short-term treatment with Epo.

Experimental Design

This study was part of a larger clinical trial in which hematopoietic and non-hematopoietic effects of EPO treatment for short and long term are assessed in CRS patients. Therefore, patients were randomized into 3 groups: (1) EPO, patients are kept on baseline low hemoglobin levels by phlebotomy for 6 months; (2) EPO, patients may rise in hemoglobin levels to defined maximum for 6 months; (3) No EPO. This gene expression analysis is focussed on EPO's short-term (2wk) effects in a subset of included patients. Group (1) and (2) were grouped for analysis, since both groups received EPO and no phlebotomy had been performed in the first 2 weeks. Monocytes were positively isolated from peripheral whole blood with CD14+ immunomagnetic beads. Total RNA was isolated and prepared for genome wide analyses using Illumina HumanRef8 V3.0 Beadchips. In total, 48 arrays were analyzed including 12 healthy controls, 18 CRS patients at baseline and 2 weeks after study enrollment. Twelve out of 18 patients received EPO during the two weeks.

Experimental Variables

--

Controls

--

Methods

--

Additional Information

Braam B, Gaillard CA, Verhaar MC, Jie KE, Wesseling S, van der Putten K

Microarray
Illumina HumanRef-8 v3
48 Samples Loaded: 48
Human (Homo sapiens)
Monocytes
Cardiorenal Syndrome (CRS)
Sample Set Spreadsheet
Please log in in order to upload files.
Samples Preview
Sample ID Age Gender !Sample_title cell type treatment group
GSM438053 38 M P4t0 monocyte EPO, kept on low hemoglobin levels
GSM438054 38 M P4t2 monocyte EPO, kept on low hemoglobin levels
GSM438055 83 F P22t0 monocyte EPO, may rise in hemoglobin levels
GSM438056 83 F P22t2 monocyte EPO, may rise in hemoglobin levels
GSM438057 71 M P6t0 monocyte No EPO
Please log in in order to upload files.
File
Raw Signal
Raw Signal
  •   |  View in GXB »
Clinical Datasource
Links

Samples Viewer / Editor

All fields are editable except the "Sample ID" column. To edit a cell, click within the cell. To edit a "date" cell, click on the calendar icon. To cancel an edit, press the ESC key.

Sample ID Age Gender !Sample Title Cell type Treatment group Patient number Timepoint (weeks) Disease
GSM438053
38
M
P4t0
monocyte
EPO, kept on low hemoglobin levels
4
0
cardiorenal syndrome (CRS)
GSM438054
38
M
P4t2
monocyte
EPO, kept on low hemoglobin levels
4
2
cardiorenal syndrome (CRS)
GSM438055
83
F
P22t0
monocyte
EPO, may rise in hemoglobin levels
22
0
cardiorenal syndrome (CRS)
GSM438056
83
F
P22t2
monocyte
EPO, may rise in hemoglobin levels
22
2
cardiorenal syndrome (CRS)
GSM438057
71
M
P6t0
monocyte
No EPO
6
0
cardiorenal syndrome (CRS)
GSM438058
71
M
P6t2
monocyte
No EPO
6
2
cardiorenal syndrome (CRS)
GSM438059
40
M
GZ25t0
monocyte
Healthy controls
Healthy25
0
healthy
GSM438060
84
F
GZ26t0
monocyte
Healthy controls
Healthy26
0
healthy
GSM438061
77
M
P17t0
monocyte
EPO, may rise in hemoglobin levels
17
0
cardiorenal syndrome (CRS)
GSM438062
77
M
P17t2
monocyte
EPO, may rise in hemoglobin levels
17
2
cardiorenal syndrome (CRS)
GSM438063
56
M
P18t0
monocyte
EPO, kept on low hemoglobin levels
18
0
cardiorenal syndrome (CRS)
GSM438064
56
M
P18t2
monocyte
EPO, kept on low hemoglobin levels
18
2
cardiorenal syndrome (CRS)
GSM438065
53
F
GZ1t0
monocyte
Healthy controls
Healthy1
0
healthy
GSM438066
76
M
GZ18t0
monocyte
Healthy controls
Healthy18
0
healthy
GSM438067
80
F
P11t0
monocyte
No EPO
11
0
cardiorenal syndrome (CRS)
GSM438068
80
F
P11t2
monocyte
No EPO
11
2
cardiorenal syndrome (CRS)
GSM438069
68
M
P15t0
monocyte
No EPO
15
0
cardiorenal syndrome (CRS)
GSM438070
68
M
P15t2
monocyte
No EPO
15
2
cardiorenal syndrome (CRS)
GSM438071
64
M
GZ9t0
monocyte
Healthy controls
Healthy9
0
healthy
GSM438072
74
F
GZ21t0
monocyte
Healthy controls
Healthy21
0
healthy
GSM438073
63
M
P7t0
monocyte
EPO, kept on low hemoglobin levels
7
0
cardiorenal syndrome (CRS)
GSM438074
63
M
P7t2
monocyte
EPO, kept on low hemoglobin levels
7
2
cardiorenal syndrome (CRS)
GSM438075
75
M
P3t0
monocyte
EPO, may rise in hemoglobin levels
3
0
cardiorenal syndrome (CRS)
GSM438076
75
M
P3t2
monocyte
EPO, may rise in hemoglobin levels
3
2
cardiorenal syndrome (CRS)
GSM438077
71
F
GZ7t26
monocyte
Healthy controls
Healthy7
0
healthy
GSM438078
69
M
GZ16t0
monocyte
Healthy controls
Healthy16
0
healthy
GSM438079
75
M
P23t0
monocyte
No EPO
23
0
cardiorenal syndrome (CRS)
GSM438080
75
M
P23t2
monocyte
No EPO
23
2
cardiorenal syndrome (CRS)
GSM438081
74
M
P9t0
monocyte
EPO, may rise in hemoglobin levels
9
0
cardiorenal syndrome (CRS)
GSM438082
74
M
P9t2
monocyte
EPO, may rise in hemoglobin levels
9
2
cardiorenal syndrome (CRS)
GSM438083
79
F
P2t0
monocyte
EPO, kept on low hemoglobin levels
2
0
cardiorenal syndrome (CRS)
GSM438084
79
F
P2t2
monocyte
EPO, kept on low hemoglobin levels
2
2
cardiorenal syndrome (CRS)
GSM438085
80
F
P12t0
monocyte
EPO, kept on low hemoglobin levels
12
0
cardiorenal syndrome (CRS)
GSM438086
73
M
P8t0
monocyte
EPO, may rise in hemoglobin levels
8
0
cardiorenal syndrome (CRS)
GSM438087
65
M
P16t0
monocyte
No EPO
16
0
cardiorenal syndrome (CRS)
GSM438088
70
M
GZ22t0
monocyte
Healthy controls
Healthy22
0
healthy
GSM438089
80
F
P12t2
monocyte
EPO, kept on low hemoglobin levels
12
2
cardiorenal syndrome (CRS)
GSM438090
73
M
P8t2
monocyte
EPO, may rise in hemoglobin levels
8
2
cardiorenal syndrome (CRS)
GSM438091
65
M
P16t2
monocyte
No EPO
16
2
cardiorenal syndrome (CRS)
GSM438092
74
M
GZ4t0
monocyte
Healthy controls
Healthy4
0
healthy
GSM438093
71
M
GZ15t0
monocyte
Healthy controls
Healthy15
0
healthy
GSM438094
81
F
P10t0
monocyte
EPO, kept on low hemoglobin levels
10
0
cardiorenal syndrome (CRS)
GSM438095
52
F
P19t0
monocyte
EPO, may rise in hemoglobin levels
19
0
cardiorenal syndrome (CRS)
GSM438096
74
M
P24t0
monocyte
No EPO
24
0
cardiorenal syndrome (CRS)
GSM438097
75
M
GZ5t0
monocyte
Healthy controls
Healthy5
0
healthy
GSM438098
81
F
P10t2
monocyte
EPO, kept on low hemoglobin levels
10
2
cardiorenal syndrome (CRS)
GSM438099
52
F
P19t2
monocyte
EPO, may rise in hemoglobin levels
19
2
cardiorenal syndrome (CRS)
GSM438100
74
M
P24t2
monocyte
No EPO
24
2
cardiorenal syndrome (CRS)

Group Sets View in Gene Expression Browser

Name  
All Samples   View
Treatment conditions Default  View
In order to make new Group Sets or change settings, please log in.

Module Analysis

Group Set  
All Samples
Treatment conditions
Your bug report has been sent!